Arranon (nelarabine)
Arranon is a nucleoside metabolic inhibitor used for the treatment of patients with T-cell acute lymphoblastic leukemia
Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arranon:
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Arranon for free until a prescription drug coverage becomes available to them.
Besponsa (inotuzumab ozogamicin) for Injection
Besponsa is a CD22-directed antibody-drug conjugate used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Pfizer Oncology Together offers 1 financial assistance program for patients using Besponsa:
Pfizer Patient Assistance Program
This program provides Besponsa free, or at a savings, for eligible patients with no healthcare coverage, as well as for patients with government insurance (who have no available independent charitable foundation support).
Blincyto (blinatumomab)
Blincyto is a bispecific CD19-directed CD3 T-cell engager used for the treatment of patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is in first or second remission, with minimal residual disease. Blincyto is also used for the treatment of patients with relapsed or refractory B-cell precursor ALL.
Amgen offers 3 financial assistance programs for patients using Blincyto:
Amgen FIRST STEP Program
With this program, eligible patients with private insurance will pay $0 for the first dose of Blincyto and $5 for each subsequent dose, with a maximum annual benefit of $20,000.
Amgen Assist 360
Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for the medication.
Amgen Safety Net Foundation
Qualifying, uninsured patients can receive Blincyto for free through Amgen’s nonprofit patient assistance program.
Erwinaze (asparaginase Erwinia chrysanthemi)
Erwinaze (asparaginase Erwinia chrysanthemi) is an asparagine-specific enzyme used for the treatment of patients with acute lymphoblastic leukemia.
Jazz Pharmaceuticals offers 1 financial assistance program for patients using Erwinaze:
JumpStart Patient Assistance Program
This program offers free Erwinaze for patients who meet the program’s requirements.
Gleevec (imatinib mesylate) Tablets
Gleevec is a kinase inhibitor used, in combination with chemotherapy, for the treatment of adults with relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) and pediatric patients with Ph+ ALL.
Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:
Novartis Oncology Universal Co-Pay Program
Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum annual benefit of $30,000.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Gleevec for free until a prescription drug coverage becomes available to them.
Iclusig (ponatinib)
Iclusig is a kinase inhibitor used for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated. Iclusig is also used for adults with Ph+ ALL and T315I mutation.
Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:
Takeda Oncology 1Point
Regardless of patients’ insurance status, this program identifies the financial assistance programs for which patients may be eligible and supports patients throughout their treatment by offering services to assist with day-to-day treatment-related concerns.
Takeda Oncology Co-Pay Assistance Program
Eligible patients with private insurance will pay only a $10 per month copay or coinsurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription, up to a maximum annual benefit of $25,000.
Kymriah (tisagenlecleucel)
Kymriah is a CD19-directed genetically modified CAR T-cell immunotherapy used for the treatment of young patients (up to age 25) with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
Novartis’ Patient Assistance NOW offers 1 financial assistance program for patients using Kymriah:
Kymriah Cares
This program offers financial assistance to eligible patients to help them access Kymriah. Patients must meet program eligibility criteria to qualify for support. Patients should work with their treatment center to submit a Service Request Form for Patient Support to Kymriah Cares.
Marqibo (vincristine sulfate liposome)
Marqibo is a vinca alkaloid used for the treatment of adult patients with Ph-negative acute lymphocytic leukemia (ALL).
Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Marqibo:
STAR Co-Pay Assistance
Eligible, privately insured patients will pay $0 for the first injection of Marqibo and then $25 for each subsequent injection, with a maximum benefit of up to $10,000 annually.
STAR Patient Assistance Program
This program provides Marqibo free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.
Sprycel (dasatinib)
Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ acute lymphoblastic leukemia.
Bristol-Myers Squibb offers 2 financial assistance programs for patients using Sprycel:
Sprycel Assist One Card
This card offers benefits for cash-paying patients, privately insured patients, and patients with public or government insurance. Privately insured patients can receive Sprycel.
Bristol-Myers Squibb Patient Assistance Foundation
Patients who don’t have public or private insurance that helps to pay for Sprycel may be eligible for help paying for their medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.
Daurismo (glasdegib) Tablets
Daurismo is a hedgehog pathway inhibitor used, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adults age 75 years or older, and in patients whose comorbidities prevent them from using intensive induction chemotherapy.
Pfizer Oncology Together offers 2 financial assistance programs for patients using Daurismo:
Pfizer Oncology Together Co-Pay Savings Program
This program assists eligible, privately insured patients with their monthly copay for Daurismo, with a maximum annual benefit of $25,000.
Pfizer Patient Assistance Program
Through this program, patients who are uninsured may qualify to receive Daurismo for free or at a savings. Eligible patients who have government insurance may also receive Daurismo for free if they cannot find financial support from an independent charitable foundation.
Idamycin PFS (idarubicin hydrochloride)
Idamycin PFS is used, in combination with other approved antileukemic drugs, for the treatment of patients with acute myeloid leukemia.
Pfizer Oncology Together offers 1 financial assistance program for patients using Idamycin PFS:
Pfizer RxPathways
Patients who are prescribed a Pfizer specialty medicine, such as Idamycin PFS, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.
Idhifa (enasidenib) Tablets
Idhifa is an IDH2 inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia with an IDH2 mutation.
Celgene offers 2 financial assistance programs for patients using Idhifa:
Celgene Commercial Co-pay Program
This program can reduce prescription copay to $25 and provides up to $10,000 per calendar year to cover copay or coinsurance costs for patients with private insurance.
Celgene Patient Assistance Program
Patients with no insurance or not enough insurance to cover their medication who meet certain financial criteria may receive Idhifa at no cost.
Mylotarg (gemtuzumab ozogamicin) for Injection
Mylotarg is a CD33-directed antibody-drug conjugate used for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults, and relapsed or refractory CD33-positive AML in patients age 2 years or older.
Pfizer Oncology Together offers 1 financial assistance program for patients using Mylotarg:
Pfizer Patient Assistance Program
Eligible patients who do not have insurance and are unable to afford Mylotarg may receive their medicine free or at a savings through this program.
Rydapt (midostaurin) Capsules
Rydapt is a kinase inhibitor used, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for the treatment of adults with acute myeloid leukemia and FLT3 mutation.
Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:
Novartis Oncology Universal Co-Pay Card Program
For eligible patients with private insurance, this copay card ensures a prescription copay of $10 per month. Novartis pays the remaining balance until the annual maximum of $15,000 is met.
Rydapt Now Access Program
For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Rydapt for free until a prescription drug coverage becomes available to them.
Tibsovo (ivosidenib)
Tibsovo is an IDH1 inhibitor used for the treatment of adults aged 75 or older or those who have comorbidities that preclude use of intensive induction chemotherapy who are newly diagnosed with acute myeloid leukemia (AML) and a susceptible IDH1 mutation, as detected by an FDA-approved test. Tibsovo is also used for the treatment of adults with relapsed or refractory AML associated with an IDH1 mutation.
myAgios Patient Support Services offers 4 financial assistance programs for patients using Tibsovo:
myAgios Commercial $25 Co-Pay Program
Eligible, privately insured patients will pay no more than $25 per Tibsovo prescription, with a maximum annual benefit of $25,000.
myAgios Patient Assistance Program
Patients who meet certain financial criteria and are uninsured or underinsured can receive Tibsovo free of charge through this program.
myAgios Quick Start Program
Patients who have private or government insurance that has been delayed by 5 or more business days may qualify to receive a free 14-day prescription of Tibsovo, up to 3 refills, for a total of 56 days of Tibsovo therapy.
myAgios Coverage Interruption Program
Eligible patients experiencing an interruption in their insurance coverage after having received at least 1 prescription through a commercial insurance will receive a free 30-day supply of Tibsovo, up to 2 refills, for a total of 90 days of Tibsovo.
Venclexta (venetoclax tablets)
Venclexta is a BCL-2 inhibitor used, in combination with azacitidine, decitabine, or low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients age 75 years or older, or in patients with AML whose comorbidities prevent them from using intensive induction chemotherapy.
Genentech offers 2 financial assistance programs for patients using Venclexta:
Genentech BioOncology Co-pay Assistance Program
For privately insured patients, this program ensures a $5 copay for Venclexta, with up to a $25,000 benefit annually. This program has no income requirements.
Genentech Patient Foundation
This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Venclexta is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.
Vyxeos (daunorubicin + cytarabine) Liposome for Injection
Vyxeos is a liposomal combination of daunorubicin (an anthracycline topoisomerase inhibitor) and cytarabine (a nucleoside metabolic inhibitor) used for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.
Jazz Pharmaceuticals’ JazzCares program offers 2 financial assistance programs for patients who are prescribed Vyxeos:
JazzCares Out-of-Pocket Assistance
Patients with private insurance may qualify for assistance with out-of-pocket costs for Vyxeos.
JazzCares Patient Assistance Program
This program offers Vyxeos at no cost for patients who are uninsured or do not have coverage for Vyxeos. Patients must have a total household gross income of less than 400% of the federal poverty level. The benefit is subject to an annual maximum.
Xospata (gilteritinib)
Xospata is a kinase inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia and FLT3 mutation, as detected by an FDA-approved test.
Xospata Support Solutions offers 3 financial assistance programs for patients using Xospata:
Xospata Copay Card Program
Eligible patients who have private insurance will pay as little as $0 per prescription of Xospata, with a maximum annual benefit of $25,000. This program has no income requirements.
Xospata Quick Start+ Program
This program provides a one-time, 7-day supply of Xospata at no cost to eligible patients who have private insurance and are experiencing an insurance-related delay in receiving their medication.
Astellas Patient Assistance Program
Through this program, patients who are uninsured or have insurance that excludes coverage for Xospata may qualify to receive their medication at no cost.
Zarxio (filgrastim-sndz)
Zarxio a biosimilar to Neulasta, is a leukocyte growth factor used to reduce the time to neutrophil recovery and the duration of fever in patients with acute myeloid leukemia, after induction or consolidation chemotherapy treatment.
Sandoz One Source offers 1 financial assistance program for patients using Zarxio:
Sandoz One Source Commercial Co-Pay Program
Through this program, privately insured patients will pay $0 copay for the first dose of Zarxio and for subsequent doses, with a maximum benefit of $10,000 annually. There is no income eligibility requirement.
Arzerra (ofatumumab)
Arzerra is a CD20-directed cytolytic monoclonal antibody used for the treatment of patients with chronic lymphocytic leukemia. In certain cases, Arzerra is used in combination with chlorambucil, or fludarabine and cyclophosphamide.
Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arzerra:
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Arzerra for free until a prescription drug coverage becomes available to them.
Bendeka (bendamustine HCl) Injection
Bendeka is an alkylating drug used for the treatment of patients with chronic lymphocytic leukemia.
Teva offers 1 financial assistance program for patients using Bendeka:
Teva Cares Foundation Patient Assistance Program
Patients without prescription drug coverage who meet specific financial criteria may receive Bendeka for free. The financial criteria specify that the patient’s annual income must not exceed $60,700 for 1 person, $82,300 for 2 people, $103,900 for 3 people, $125,500 for 4 people, or $147,100 for 5 people.
Calquence (acalabrutinib) Capsules
Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with chronic lymphocytic leukemia.
AstraZeneca 360 offers 2 financial assistance program for patients who are using Calquence:
CALQUENCE Co-pay Savings Program
Eligible patients who have private insurance will pay $0 per month and may have access to up to $26,000 annually to assist with the out-of-pocket prescription costs associated with Calquence.
AZ&Me Prescription Savings Program
This program offers free medication from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medication through participating healthcare facilities.
Copiktra (duvelisib)
Copiktra is a dual PI3 kinase inhibitor used for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia, after at least 2 other therapies.
Verastem Cares offers 3 financial assistance programs for patients using Copiktra:
Verastem Cares Co-Pay Assistance
Patients who have private insurance may pay as little as $5 for their prescription of Copiktra, with a maximum annual benefit of $25,000. This program has no patient income requirement.
Verastem Cares Bridge Rx Program
This program provides a free 14-day supply of Copiktra to eligible patients who experience coverage delays or loss of insurance of longer than 5 days.
Verastem Cares Patient Assistance Program
Patients who are uninsured and have an annual income of $150,000 or less may qualify to receive Copiktra for free.
Gazyva (obinutuzumab)
Gazyva is a CD20-directed cytolytic antibody used, in combination with chlorambucil, for the treatment of patients with untreated chronic lymphocytic leukemia (CLL). Gazyva is also used, in combination with Imbruvica or with Venclexta, for the first-line treatment of patients with CLL.
Genentech offers 2 financial assistance programs for patients using Gazyva:
Genentech BioOncology Co-pay Assistance Program
The program ensures a $5 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.
Genentech Patient Foundation
This foundation provides Gazyvafree of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.
Imbruvica (ibrutinib) Capsules/Tablets
Imbruvica is a Bruton tyrosine kinase inhibitor used for the first-line treatment of patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion. Imbruvica is also used, in combination with Gazyva, for the first-line treatment of patients with CLL.
Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:
You&i Instant Savings Program
Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and coinsurance medication costs for Imbruvica.
Johnson & Johnson Patient Assistance Foundation
This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.
Rituxan (rituximab)
Rituxan is a CD20-directed cytolytic antibody used, in combination with fludarabine and cyclophosphamide, for the treatment of patients with chronic lymphocytic leukemia.
Rituxan is also used, in combination with Venclexta, for first-line treatment of CLL. is also used, in combination with Venclexta, for first-line treatment of CLL.
Genentech offers 2 financial assistance programs for patients using Rituxan:
Genentech BioOncology Co-pay Assistance Program
The program ensures a $5 copay for Rituxan for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.
Genentech Patient Foundation
This foundation provides Rituxan free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Rituxan is also provided free for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.
Rituxan Hycela (rituximab/hyaluronidase human) Injection
Rituxan Hycela is a combination of rituximab (a CD20-directed cytolytic antibody) and hyaluronidase human (an endoglycosidase) that is used, in combination with fludarabine and cyclophosphamide, for the treatment of untreated adults with chronic lymphocytic leukemia (CLL) and of previously treated CLL.
Genentech offers 2 financial assistance programs for patients using Rituxan Hycela:
Genentech BioOncology Assistance Program
PPrivately insured patients will pay only a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was refilled within 120 days before enrollment in this program.
Genentech Patient Foundation
This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For household with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.
Venclexta (venetoclax) Tablets
Venclexta is a BCL-2 inhibitor used for the treatment of patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion, who have received at least 1 therapy. Venclexta is also used, in combination with with Gazyva or with rituximab, for the first-line treatment of patients with CLL.
Genentech offers 2 financial assistance programs for patients using Venclexta:
Genentech BioOncology Co-pay Assistance Program
The program ensures a $5 copay for Venclexta for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.
Genentech Patient Foundation
This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Venclexta is also provided free for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.
Zydelig (idelalisib) Tablets
Zydelig is a kinase inhibitor used, in combination with Rituxan, for the treatment of patients with relapsed chronic lymphocytic leukemia.
Zydelig AccessConnect offers 3 financial assistance programs for patients using Zydelig:
Zydelig AccessConnect Copay Coupon Card
Patients with private insurance and copays above $5 are eligible for this program. With the Copay Coupon Card, patients will pay only the first $5 per prescription fill of Zydelig. The maximum benefit allowed is 25% of the catalog price for a 12-month supply of Zydelig.
Zydelig QuickStart Program
The Zydelig QuickStart Program gives eligible patients who have an insurance coverage delay of more than 5 business days quick access to a free, one-time, 30-day supply of Zydelig.
Zydelig AccessConnect Patient Assistance Program
Patients with no insurance or who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.
Bosulif (bosutinib)
Bosulif is a kinase inhibitor used for the treatment of adult patients with Ph+ chronic myeloid leukemia in the chronic, accelerated, or blast phase.
Pfizer Oncology Together offers 2 financial assistance programs for patients using Bosulif:
Pfizer Oncology Together Co-Pay Savings Program
This Pfizer program assists eligible patients with private insurance so that their copay for Bosulif is $0 monthly, with a maximum savings of up to $25,000 annually.
Pfizer Patient Assistance Program
This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Bosulif for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Bosulif for free.
Gleevec (imatinib mesylate) Tablets
Gleevec is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia in chronic, blast crisis, or accelerated phase, or in chronic phase after the failure of interferon-alpha therapy.
Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleeve::
Novartis Oncology Universal Co-Pay Program
Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Gleevec for free until a prescription drug coverage becomes available to them.
Iclusig (ponatinib)
Iclusig is a kinase inhibitor used for the treatment of adults with chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML). Iclusig is also used for adults with chronic-, accelerated-, or blast-phase CML with T315I mutation.
Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:
Takeda Oncology 1Point
Regardless of patients’ insurance status, this program identifies the financial assistance programs for Iclusig for which patients may be eligible and supports patients throughout their treatment by offering services to assist with day-to-day treatment-related concerns.
Takeda Oncology Co-Pay Assistance Program
Eligible patients with private insurance will pay only a $10 per month copay or coinsurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription up to a maximum annual benefit of $25,000.
Sprycel (dasatinib)
Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia.
Bristol-Myers Squibb offers 2 financial assistance programs for patients using Sprycel:
Sprycel Assist One Card
This card offers benefits for cash-paying patients, privately insured patients, and patients with public or government insurance. Privately insured patients can receive Sprycel with a reduced copay, in some cases $0 a month, up to a maximum annual benefit of $32,000. New cash-paying patients or new patients covered by a government-funded program are eligible for a free 30-day trial supply of Sprycel.
Bristol-Myers Squibb Patient Assistance Foundation
Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Sprycel, may be eligible for help paying for their prescription if they are receiving treatment as an outpatient and have an annual income up to 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.
Synribo (omacetaxine)
Synribo is used for the treatment of adults with chronic- or accelerated-phase chronic myeloid leukemia.
Teva offers 1 financial assistance program for patients using Synribo:
Teva Cares Foundation Patient Assistance Program
Patients without prescription drug coverage who meet specific financial criteria may receive Synribo for free. The financial criteria specify that the patient’s annual income must not exceed $60,700 for 1 person, $82,300 for 2 people, $103,900 for 3 people, $125,500 for 4 people, or $147,100 for 5 people.
Tasigna (nilotinib)
Tasigna is a kinase inhibitor used for the treatment of patients older than 1 year with newly diagnosed chronic-phase Ph+ chronic myeloid leukemia (CML), or for patients older than 1 year with chronic-phase Ph+ CML that is resistant to previous tyrosine kinase inhibitor therapy. Tasigna is also used for adults with chronic-phase or accelerated-phase Ph+ CML that is resistant to or who are intolerant of Gleevec.
Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Tasigna:
Novartis Oncology Universal Co-Pay Program
Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Tasigna. The program pays the remaining balance until an annual maximum of $15,000 is met.
Tasigna 3 Months Free Trial Voucher
Eligible new patients can receive a free 3-month trial supply of Tasigna capsules.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients must be without insurance, be US citizens, and provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Tasigna for free until a prescription drug coverage becomes available to them.
Lumoxiti (moxetumomab pasudotox-tdfk)
Lumoxiti is a CD22-directed cytotoxin used for the treatment of adults with relapsed or refractory hairy-cell leukemia who have received at least 2 systemic therapies, including a purine nucleoside analog.
AstraZeneca Access 360 offers 1 financial assistance program for patients who have been prescribed Lumoxiti:
Access 360 Lumoxiti Patient Savings Program
Although the patient’s out-of-pocket costs may vary, this program aims for eligible patients to pay $0 per infusion of Lumoxiti, with a maximum annual savings of $26,000. Eligible patients must have private health insurance that partially covers the costs of Lumoxiti.
Rydapt (midostaurin) Capsules
Rydapt is a kinase inhibitor used for the treatment of adults with mast-cell leukemia.
Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:
Novartis Oncology Universal Co-Pay Card Program
For eligible patients with private insurance, this copay card ensures a prescription copay of $25 per month. Novartis pays the remaining balance until the annual maximum of $15,000 is met.
Rydapt Now Access Program
For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Rydapt for free until a prescription drug coverage becomes available to them.
Table. Drugs Prescribed for Leukemia
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Arranon (nelarabine)
- Novartis
- T-cell ALL
- Novartis Patient Assistance Foundation
800-277-2254
- Besponsa (inotuzumab ozogamicin) for Injection
- Pfizer
- Relapsed or refractory B-cell precursor ALL
- Pfizer Patient Assistance Program
877-744-5675
- Blincyto (blinatumomab)
- Amgen
- B-cell precursor ALL
- Amgen FIRST STEP Program
888-657-8371
Amgen Assist 360
Amgen Safety Net Foundation
888-762-6436
- Erwinaze (asparaginase Erwinia chrysanthemi)
- Jazz Pharmaceuticals
- ALL
- JumpStart Patient Assistance Program
888-837-4397
- Gleevec (imatinib mesylate) Tablets
- Novartis
- Ph+ ALL
- Novartis Oncology Universal Co-Pay Program
866-453-3832
Novartis Patient Assistance Foundation
800-277-2254
- Iclusig (ponatinib)
- Takeda Oncology
- Adults with Ph+ ALL or with Ph+ ALL and T315I mutation
- Takeda Oncology 1Point
Takeda Oncology Co-Pay Assistance Program
844-817-6468
- Kymriah (tisagenlecleucel)
- Novartis
- B-cell precursor ALL in patients up to age 25
- Kymriah Cares
844-459-6742
- Marqibo (vincristine sulfate liposome)
- Acrotech Biopharma
- Treatment of Ph-negative ALL
- STAR Co-Pay Assistance
888-537-8277
STAR Patient Assistance Program
888-537-8277
- Sprycel (dasatinib)
- Bristol-Myers Squibb
- Ph+ ALL
- Sprycel Assist One Card
855-777-9235
Bristol-Myers Squibb Patient Assistance Foundation
800-736-0003
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Daurismo (glasdegib) Tablets
- Pfizer
- AML in patients older than 75 or AML and comorbidities preventing use of intensive chemotherapy
- Pfizer Oncology Together Co-Pay Savings Programm
Pfizer Patient Assistance Program
877-744-5675
- Idamycin PFS (idarubicin hydrochloride)
- Pfizer
- AML
- Pfizer RxPathways
866-706-2400
- Idhifa (enasidenib) Tablets
- Celgene
- AML with IDH2 mutation
- Celgene Commercial Co-pay Program
Celgene Patient Assistance Program
800-931-8691
- Mylotarg (gemtuzumab ozogamicin) for Injection
- Pfizer
- CD33-positive AML in adults
Relapsed or refractory CD33-positive AML in patients age 2 or older - Pfizer Patient
Assistance Program
877-744-5675
- Rydapt (midostaurin) Capsules
- Novartis
- AML with FLT3 mutation, in combination with standard chemotherapy
- Novartis Oncology Universal Co-Pay Program
877-577-7756
Rydapt Now Access Program
800-282-7630
Novartis Patient Assistance Foundation
800-277-2254
- Tibsovo (apalutamide)
- Agios Pharmaceuticals
- First-line treatment of AML with IDH1 mutation in adults 75 or older or those with comorbidities precluding intensive chemotherapy
Relapsed or refractory AML with IDH1 mutation - myAgios Commercial $25 Co-Pay Program
myAgios Patient Assistance Program
myAgios Quick Start Program
myAgios Coverage Interruption Program
844-409-1141
- Venclexta (ventoclax tablets)
- AbbVie/Genentech
- AML in patients older than 75 or AML and comorbidities preventing use of intensive chemotherapy
- Genentech BioOncology Assistance Program
866-422-2377
Genentech Patient Foundation
866-422-2377
- Vyxeos (daunorubicin and cytarabine) Liposome for Injection
- Jazz Pharmaceuticals
- Therapy-related AML
AML with myelodysplasia related changes - JazzCares Out-of-Pocket Assistance
JazzCares Patient Assistance Program
855-589-9367
- Xospata (gilteritinib)
- Astellas
- Relapsed or refractory AML with FLT3 mutation
- Xospata Copay Card Program
844-632-9272
Xospata Quick Start+ Program
844-632-9272
Astellas Patient Assistance Program
844-632-9272
- Zarxio (filgrastim-sndz)
- Sandoz
- Treatment of AML
- Sandoz One Source Co-Pay Program
844-726-3691
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Arzerra (ofatumumab)
- Novartis
- CLL, sometimes in combination with chlorambucil, or with fludarabine + cyclophosphamide
- Novartis Patient Assistance Foundation
800-277-2254
- Bendeka (bendamustine hydrochloride) Injection
- Teva
- Treatment of CLL
- Teva Cares Foundation Patient Assistance Program
877-237-4881
- Calquence (acalabrutinib) Capsules
- AstraZeneca
- Treatment of CLLL
- Calquence Co-pay Savings Program
AZ&Me Prescription Savings Program
844-275-2360
- Copiktra (duvelisib)
- Verastem
- Relapsed or refractory CLL
- Verastem Cares Co-Pay Assistance
Verastem Cares Bridge Rx Program
Verastem Cares Patient Assistance Program
833-570-2273
- Gazyva (obinutuzumab)
- Genentech
- First-line treatment of CLL, in combination with Imbruvica
First-line treatment of CLL, in combination with Venclexta
Treatment of CLL, in combination with chlorambucil - Genentech BioOncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Imbruvica (ibrutinib) Capsules/Tablets
- Pharmacyclics
- First-line treatment of CLL, with or without 17p deletion
First-line treatment of CLL, in combination with Gazyva - You&i Instant Savings Program
877-877-3536
Johnson & Johnson Patient Assistance Foundation
800-652-6227
- Rituxan (rituximab)
- Genentech
- Treatment of CLL, in combination with fludarabine and cyclophosphamide
First-line treatment of CLL, in combination with Venclexta - Genentech BioOncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Rituxan Hycela (rituximab/hyaluronidase human) Injection
- Genentech
- Treatment of CLL, in combination with fludarabine and cyclophosphamide
- Genentech BioOncology
Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Venclexta (venetoclax) Tablets
- AbbVie/Genentech
- Treatment of CLL with or without 17p deletion, after 1 therapy
First-line treatment of CLL, in combination with Gazyva or with rituximab - Genentech BioOncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Zydelig (idelalisib) Tablets
- Gilead
- Relapsed CLL, in combination with Rituxan
- Zydelig AccessConnect Copay Coupon Card
844-622-2377
Zydelig QuickStart Program
844-622-2377
Zydelig AccessConnect Patient Assistance Program
844-622-2377
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Bosulif (bosutinib)
- Pfizer
- Treatment of Ph+ CML
- Pfizer Oncology Together Co-Pay Savings Program
877-744-5675
Pfizer Patient Assistance Program
877-744-5675
- Gleevec (imatinib mesylate) Tablets
- Novartis
- Treatment of Ph+ CML
- Novartis Oncology Universal Co-Pay Program
866-453-3832
Novartis Patient Assistance Foundation
800-277-2254
- Iclusig (ponatinib)
- Takeda Oncology
- Adults with chronic-, accelerated-, or blast-phase CML
Adults with chronic-, accelerated-, or blast-phase CML with T315I mutation - Takeda Oncology 1Point
844-817-6468
Takeda Oncology Co-Pay Assistance Program
844-817-6468
- Sprycel (dasatinib)
- Bristol-Myers Squibb
- Treatment of Ph+ CML
- Sprycel Assist One Card
855-777-9235
Bristol-Myers Squibb Patient Assistance Foundation
800-736-0003
- Synribo (omacetaxine)
- Teva
- Adults with chronic- or acceleratedphase CML
- Teva Cares Foundation Patient Assistance Program
877-237-4881
- Tasigna (nilotinib)
- Novartis
- Newly diagnosed chronic-phase Ph+ CML in patients older than 1 year
Patients older than 1 year with chronic-phase Ph+ CML that is resistant to previous tyrosine kinase inhibitor therapy
Adults with chronic- or accelerated-phase Ph+ CML that is resistant to, or who are intolerant of, Gleevec - Novartis Oncology Universal Co-Pay Program
Tasigna 3 Months Free Trial Voucher
877-577-7756
Novartis Patient Assistance Foundation
800-277-2254
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Lumoxiti (moxetumomab pasudotox-tdfk)
- AstraZeneca
- Relapsed or refractory hairy-cell leukemia after systemic therapy
- Access 360 Lumoxiti Patient Savings Program
844-275-2360
- Drug name (generic name)
- Drug company
- Indication
- Patient support services
- Rydapt (midostaurin) Capsules
- Novartis
- Treatment of Mast-cell leukemia
- Novartis Oncology Universal Co-Pay Program
877-577-7756
Rydapt Now Access Program
800-282-7630
Novartis Patient Assistance Foundation
800-277-2254